文章：

透明细胞肾细胞癌的诊断与治疗现状

The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma

原文发布日期：1 December 2024

DOI: 10.3390/cancers16234034

类型: Article

开放获取: 是

英文摘要：

Clear cell renal cell carcinoma is the most common form of kidney cancer, accounting for 75% of malignant kidney tumors, and is generally associated with poor patient outcomes. With risk factors including smoking, obesity, and hypertension, all of which have a high prevalence in the United States and Europe, as well as genetic factors including tuberous sclerosis complex and Von Hippel–Lindau syndrome, there is an increasing need to expand our present understanding. The current clear cell renal cell carcinoma knowledge is outdated, with obsolete diagnostic criteria and moderately invasive surgical treatments still prevailing, partially ascribed to its resistance to chemotherapy and radiation therapy. The standard of treatment relies on surgical intervention, including radical nephrectomy and partial nephrectomy, while more recent treatments target neoplastic growth pathways and immune regulation checkpoints.

摘要翻译： 

透明细胞肾细胞癌是最常见的肾癌类型，占恶性肾脏肿瘤的75%，通常与患者不良预后相关。其风险因素包括吸烟、肥胖和高血压（这些因素在欧美地区发病率较高），以及结节性硬化症和希佩尔-林道综合征等遗传因素，这促使我们亟需拓展当前认知。现有透明细胞肾细胞癌知识体系已显陈旧，过时的诊断标准与具有中度侵入性的手术治疗仍占主导地位，部分归因于其对化疗和放疗的抵抗性。当前治疗标准依赖于手术干预，包括根治性肾切除术和部分肾切除术，而新兴疗法主要针对肿瘤生长通路和免疫调节检查点。

原文链接：

The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma